You are here

Jay and Silent Bob Enter the Cannabis Products Market -- CFN Media

SEATTLE, Dec. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering the multiyear cannabis product licensing, development, and marketing agreement between Chemesis International Inc. (CSE: CSI) (OTC: CADMF) and the team of Kevin Smith and Jason Mewes. The two actors are better known as Jay and Silent Bob from slacker film classics such as Clerks, Mallrats, and Chasing Amy.  The initial brand is called Jay and Silent Bob’s Private Stash. Chemesis is a legal cannabis company with vertically-integrated operations and established brands in California and Puerto Rico. The company has plans to expand beyond those markets throughout the United States and into Latin America.

One thing that may serve to differentiate companies in the ever-expanding legal cannabis market is branding. Consumers identify with brands, and creating brand loyalty is job #1 for consumer products companies. It’s no different with legal cannabis as the industry continues to emerge from its black market roots. One tried and true marketing strategy is to utilize industry-appropriate celebrities (and their active social media followers) to create a unique brand identity.

Click here to stay up to date with Chemesis International corporate developments.

Cultural Credibility and Social Media Following

The Jay and Silent Bob characters were created by Kevin Smith, who also directed the movies that made them famous. Since the run of movie success died out a bit in the early 2000s, Smith especially has branched out into the world of social media, podcasts, and even television. Throughout all of his endeavors, cannabis has been a constant theme. Smith and Mewes launched their continuing Jay and Silent Bob Get Old podcast in 2010, and Smith is involved with a number of other diverse podcasts. Smith recently developed a TV pilot called Hollyweed (focused on the lives of two LA-area dispensary owners), has been directing a number of television episodes for a variety of series, and will be releasing a Jay and Silent Bob Reboot movie in 2019. Between the two, they have over 12 million social media followers. They have set up a new Instagram page that highlights the Jay and Silent Bob’s Private Stash brand.

In short, Kevin Smith ‘conquered’ Hollywood from the outside with his immensely successful string of movies. Instead of selling out, he has maintained cultural viability by embracing his outsider status, utilizing emerging content platforms to continue his unique contributions to the ongoing cultural conversation around cannabis culture. Chemesis offers an opportunity to broaden his reach into consumer cannabis products.

“Kevin Smith is many things to many people,” said Edgar Montero, CEO of Chemesis.  “To us, he is one of the most prolific content creators of our generation and the foremost authority on all things comedy, comics, and superfandom. His fans respect him because he views the world with a critical eye for excellence and authenticity, but he also is able to sit back and enjoy the moment.  What better way to enjoy the moment than with our products, and what better critics to assure their quality than Kevin and Jay.”

Click here to stay up to date with Chemesis International corporate developments.

Chemesis’ Infrastructure

Chemesis offers a fully-licensed and integrated infrastructure in California that should serve as an ideal platform for the intended Q1 2019 product launch. In partnership with Smith and Mewes, Chemesis plans to introduce and market a full line of products including flower, oils, extracts, pre-rolls, and edibles.

The company owns 80% of SAP Global and its fully licensed production facility in the Coachella Valley of Southern California. The factory has the capacity to turn out 200 pounds of cannabis oil each day, with complementary packaging and manufacturing abilities as well. Chemesis fully owns and distributes the associated California Sap line of products, including award-winning CO2 extracts, the innovative Gramqul packaging system for oil, and a line of vaporizers.

Chemesis also owns 100% of Desert Zen Fulfillment, another Coachella Valley operation that boasts manufacturing, packaging, and distribution capabilities. Desert Zen has an extensive California distribution network, giving Chemesis fully licensed control over the product life cycle from formulation through distribution.

Looking Ahead

The marriage between Chemesis and Smith/Mewes has the potential to leverage the best of both entities to create a consumer product powerhouse. California is the place to build a consumer brand, and Chemesis is already set up there with the nuts-and-bolts infrastructure in place combined with existing brands in the market. The addition of products branded and promoted by pop culture icons could be a heady mix as the cannabis industry continues to expand beyond its black market roots into a more widespread and accepted place in American culture.

Click here to stay up to date with Chemesis International corporate developments.

Please follow the link to read the full article: http://www.cannabisfn.com/jay-and-silent-bob-enter-the-cannabis-products-market/

About CFN Media

CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Frank Lane
206-369-7050
flane@cannabisfn.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/76e65f4d-ab20-4ee3-bfa3-f2b36e1865bf

Wednesday, December 5, 2018 - 09:00

More Headlines

BTC Is a Group of Rare Gastrointestinal Cancers With Limited Treatment Options, Poor Outcomes
Study Demonstrates Rapid Response in Patients, and Doesn’t Affect Tamoxifen Efficacy
Prescription App Can Serve As Training, Monitoring, and Reminder Tool
Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection